Our mission is to make the production of complex therapeutic proteins, biologics and viral vectors more efficient and cost-effective, enabling developers and manufacturers to bring innovative products to patients worldwide.
We are an entrepreneurial, science-driven technology company focused on improving biologics and viral vector production. We develop proprietary vector and transposase technologies that address complex expression and cell line development challenges, helping our clients increase productivity and improve the commercial viability of promising products.
By enabling more efficient and cost-effective manufacturing, our technologies support the development of new therapeutic proteins, biologics and viral vector products for patients worldwide.
ProteoNic licenses proprietary bioproduction technologies to pharmaceutical and biotechnology companies and CDMOs worldwide. Headquartered in Leiden, one of Europe’s leading life sciences hubs, ProteoNic operates within a strong innovation ecosystem
The 2G UNic® Platform combines optimised vector architecture with efficient transposase-mediated gene integration to deliver higher titers, faster cell line development and stable manufacturing performance.
The platform can be adopted as a complete technology solution or integrated modularly into established cell line development workflows. The 2G UNic vector technology can also be combined with existing transposon and targeted-integration systems, allowing clients to improve expression without replacing their established production platforms.
In addition to therapeutic protein production, ProteoNic’s technologies can be applied to viral vector manufacturing, including the development of more productive packaging and producer cell lines.
The 2G UNic Platform has demonstrated increased expression across stable pools and clones and across a broad range of molecule formats, including monoclonal antibodies, biosimilars, Fc-fusion proteins, bispecific antibodies and other difficult-to-express biologics.
ProteoNic’s technologies are designed to fit seamlessly into established cell line development and manufacturing workflows. Improved productivity can reduce production costs, release manufacturing capacity and support the commercially viable manufacture of challenging products.
The technologies are available through product-specific and platform licences on a non-exclusive, worldwide basis.
ProteoNic’s 2G UNic Platform increases production levels across a broad range of therapeutic proteins, including monoclonal antibodies, biosimilars and more difficult-to-express molecules such as Fc-fusion proteins and bispecific antibodies.
Independent technical and commercial validation by leading biopharmaceutical companies and development partners has demonstrated severalfold improvements in productivity across multiple cell lines, expression systems and molecule formats.
These improvements can generate substantial commercial value by reducing production costs, releasing manufacturing capacity and improving the economic viability of challenging biologic products. For commercial-scale products, the resulting savings can amount to several million euros annually.
Beyond mammalian protein production, ProteoNic’s vector and transposase technologies also have applications in viral vector manufacturing and protein production in yeast, where improved yields can create significant value for developers and manufacturers.
CEO
